Editorial: Bringing GERD management up to PAR-2

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Proton pump inhibitors (PPIs) are extremely effective for mucosal healing of reflux esophagitis, but less so for relieving the symptom of heartburn. PPIs block the secretion of gastric acid, the caustic effects of which have been assumed to be the primary culprit in the pathogenesis of reflux esophagitis. However, mounting data suggest that reflux-stimulated, immune-mediated mechanisms may underlie the development of esophagitis in patients with gastroesophageal reflux disease (GERD). Thus, the future of GERD therapy, particularly for patients who are refractory to PPIs, may be the targeting of proteins such as proteinase-activated receptor-2, which have central roles in the generation of immune-mediated esophageal mucosal damage and in eliciting the symptom of heartburn.

Original languageEnglish (US)
Pages (from-to)1944-1946
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume105
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Proton Pump Inhibitors
Disease Management
Gastroesophageal Reflux
Heartburn
Peptic Esophagitis
PAR-2 Receptor
Caustics
Esophagitis
Gastric Acid
Protein Transport
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Editorial : Bringing GERD management up to PAR-2. / Souza, Rhonda F.

In: American Journal of Gastroenterology, Vol. 105, No. 9, 09.2010, p. 1944-1946.

Research output: Contribution to journalArticle

@article{4d28c8f2795342e4a34cf3b94219236b,
title = "Editorial: Bringing GERD management up to PAR-2",
abstract = "Proton pump inhibitors (PPIs) are extremely effective for mucosal healing of reflux esophagitis, but less so for relieving the symptom of heartburn. PPIs block the secretion of gastric acid, the caustic effects of which have been assumed to be the primary culprit in the pathogenesis of reflux esophagitis. However, mounting data suggest that reflux-stimulated, immune-mediated mechanisms may underlie the development of esophagitis in patients with gastroesophageal reflux disease (GERD). Thus, the future of GERD therapy, particularly for patients who are refractory to PPIs, may be the targeting of proteins such as proteinase-activated receptor-2, which have central roles in the generation of immune-mediated esophageal mucosal damage and in eliciting the symptom of heartburn.",
author = "Souza, {Rhonda F.}",
year = "2010",
month = "9",
doi = "10.1038/ajg.2010.272",
language = "English (US)",
volume = "105",
pages = "1944--1946",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Editorial

T2 - Bringing GERD management up to PAR-2

AU - Souza, Rhonda F.

PY - 2010/9

Y1 - 2010/9

N2 - Proton pump inhibitors (PPIs) are extremely effective for mucosal healing of reflux esophagitis, but less so for relieving the symptom of heartburn. PPIs block the secretion of gastric acid, the caustic effects of which have been assumed to be the primary culprit in the pathogenesis of reflux esophagitis. However, mounting data suggest that reflux-stimulated, immune-mediated mechanisms may underlie the development of esophagitis in patients with gastroesophageal reflux disease (GERD). Thus, the future of GERD therapy, particularly for patients who are refractory to PPIs, may be the targeting of proteins such as proteinase-activated receptor-2, which have central roles in the generation of immune-mediated esophageal mucosal damage and in eliciting the symptom of heartburn.

AB - Proton pump inhibitors (PPIs) are extremely effective for mucosal healing of reflux esophagitis, but less so for relieving the symptom of heartburn. PPIs block the secretion of gastric acid, the caustic effects of which have been assumed to be the primary culprit in the pathogenesis of reflux esophagitis. However, mounting data suggest that reflux-stimulated, immune-mediated mechanisms may underlie the development of esophagitis in patients with gastroesophageal reflux disease (GERD). Thus, the future of GERD therapy, particularly for patients who are refractory to PPIs, may be the targeting of proteins such as proteinase-activated receptor-2, which have central roles in the generation of immune-mediated esophageal mucosal damage and in eliciting the symptom of heartburn.

UR - http://www.scopus.com/inward/record.url?scp=77956322366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956322366&partnerID=8YFLogxK

U2 - 10.1038/ajg.2010.272

DO - 10.1038/ajg.2010.272

M3 - Article

C2 - 20818348

AN - SCOPUS:77956322366

VL - 105

SP - 1944

EP - 1946

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -